Anifrolumab ELISA Kit (DB823018)

Datasheet Share product Copy info

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	DB823018
Description	Anifrolumab ELISA Kit (DB823018) — Quantitative competitive ELISA for Anifrolumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Competitive Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Sample type	Plasma, Serum
Sensitivity	69.49 ng/ml
Range	93.75-6,000 ng/ml
Accession	P17181
Applications	ELISA
Detection method	Colorimetric
Assay type	Quantitative
Recovery	80-120%
Shipping	2-8 ℃
Stability and Storage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Specifications	Anifrolumab
Alternate Names	MDX-1333, MEDI-546, 1326232-46-5
Background	Interferon alpha/beta receptor 1 (Anifrolumab) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes. 1. Russell-Harde, D. et al. (1999) Biochemical and biophysical research communications 255, 539-44. PMID: 10049744 2. Kumar, KG. et al. (2003) The EMBO journal 22, 5480-90. PMID: 14532120 3. Kumar, KG. et al. (2004) The Journal of biological chemistry 279, 46614-20. PMID: 15337770 4. Uzé, G. et al. (1990) Cell 60, 225-34. PMID: 2153461 5. Thomas, C. et al. (2011) Cell 146, 621-32. PMID: 21854986 6. Zheng, H. et al. (2013) Cell reports 5, 180-93. PMID: 24075985 7. Hernandez, N. et al. (2019) The Journal of experimental medicine 216, 2057-2070. PMID: 31270247 8. Gothe, F. et al. (2022) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74, 136-139. PMID: 33252644 9. Bastard, P. et al. (2022) The Journal of experimental medicine 219. PMID: 35442418 10. Abramovich, C. et al. (1994) The EMBO journal 13, 5871-7. PMID: 7813427
Note	For Research Use Only.